A Randomized Study Comparing MDX-010 (CTLA-4) Alone or in Combination With DTIC in the Treatment of Patients With Chemotherapy Naїve Metastatic Melanoma.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
United States: Food and Drug Administration
MDX010-08
NCT00050102
October 2002
February 2004
Name | Location |
---|---|
Arizona Cancer Center | Tucson, Arizona 85724 |
USC/Norris Comprehensive Cancer Center | Los Angeles, California 90033-0800 |
Huntsman Cancer Institute | Salt Lake City, Utah 84112 |
Pacific Shores Medical Group | Long Beach, California 90813 |
Cancer Institute Medical Group | Los Angeles, California 90025 |
Northern California Melanoma Center | San Francisco, California 94109 |
Indiana Oncology/ Hematology Consultants | Indianapolis, Indiana 46237 |
Piedmont Oncology Specialists | Charlotte, North Carolina 28207 |
Joe Arrington Cancer. Research & Treatment Center | Lubbock, Texas 79410 |